Overview

A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics

Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
To study the pharmacokinetic characteristics of TQ-B3395 in the human body, recommend a reasonable regimen for subsequent research.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd